Conduit Pharmaceuticals has signed an agreement with Sarborg to leverage advanced AI and cybernetics for the optimisation of processes related to key drug development.

These include the repurposing and discovery of drugs, clinical trial monitoring and solid-form identification.

This approach helps to decrease human error, minimise costs and optimise decision-making processes.

Conduit's adoption of these tools will provide a significant competitive advantage by minimising human intervention throughout the drug development cycle.

The company will gain access to predictive models and dashboards, allowing for real-time evaluation of drug candidates and the streamlining of clinical trials.

Conduit Pharmaceuticals CEO Dr David Tapolczay stated: “By incorporating Sarborg’s cutting-edge AI and cybernetics platform, Conduit is taking a bold step forward in revolutionising our approach to drug development and asset management.

“This partnership will provide us with a strategic advantage, allowing us to identify and act on opportunities more swiftly and accurately than ever before.”

The integration of learning algorithms is projected to lead to faster, more accurate decisions, thereby improving efficiency and decreasing costs.

The partnership grants Conduit a perpetual, royalty-free, assignable and non-exclusive right to utilise any of Sarborg’s platforms or technology.  

Ongoing support from Sarborg will ensure that these systems evolve in line with Conduit's needs, fostering long-term innovation in areas such as intellectual property creation and regulatory strategy.

By adopting these forward-thinking solutions, Conduit aims to stay at the forefront of innovation, moving away from traditional methods and embracing AI technology.

As a multi-asset, clinical-stage, disease-agnostic life science company, the company is focused on delivering an efficient model for compound development.

It acquires and funds the development of assets ready for Phase II, and aims for exits through licensing deals post-successful clinical trials.

In August 2024, Conduit announced the acquisition of three first-in-class assets, AZD1656, AZD5658 and AZD5904, from AstraZeneca, under an exclusive licensing agreement.